482 related articles for article (PubMed ID: 35949435)
1. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances.
Rallis KS; Makrakis D; Ziogas IA; Tsoulfas G
World J Clin Oncol; 2022 Jun; 13(6):448-472. PubMed ID: 35949435
[TBL] [Abstract][Full Text] [Related]
2. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
3. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma.
Donne R; Lujambio A
Hepatology; 2023 May; 77(5):1773-1796. PubMed ID: 35989535
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting.
Plaz Torres MC; Lai Q; Piscaglia F; Caturelli E; Cabibbo G; Biasini E; Pelizzaro F; Marra F; Trevisani F; Giannini EG
J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34361985
[TBL] [Abstract][Full Text] [Related]
5. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
Chen Y; Hu H; Yuan X; Fan X; Zhang C
Front Immunol; 2022; 13():896752. PubMed ID: 35757756
[TBL] [Abstract][Full Text] [Related]
6. Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials.
Yu J; Li M; Ren B; Cheng L; Wang X; Ma Z; Yong WP; Chen X; Wang L; Goh BC
Front Pharmacol; 2023; 14():1261575. PubMed ID: 37719852
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in immunotherapy for hepatocellular carcinoma.
Khan AA; Liu ZK; Xu X
Hepatobiliary Pancreat Dis Int; 2021 Dec; 20(6):511-520. PubMed ID: 34344612
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapies for advanced hepatocellular carcinoma.
Sun LY; Zhang KJ; Xie YM; Liu JW; Xiao ZQ
Front Pharmacol; 2023; 14():1138493. PubMed ID: 37025485
[TBL] [Abstract][Full Text] [Related]
9. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Xu HF; Gao QZ; Yang RJ
Immunotherapy; 2021 Dec; 13(17):1395-1405. PubMed ID: 34607482
[TBL] [Abstract][Full Text] [Related]
10. The Treatment Landscape of Advanced Hepatocellular Carcinoma.
Wong KM; King GG; Harris WP
Curr Oncol Rep; 2022 Jul; 24(7):917-927. PubMed ID: 35347594
[TBL] [Abstract][Full Text] [Related]
11. A multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma.
Lee YR
J Liver Cancer; 2023 Sep; 23(2):316-329. PubMed ID: 37743048
[TBL] [Abstract][Full Text] [Related]
12. Advances in Immunotherapy for Hepatocellular Carcinoma (HCC).
Bicer F; Kure C; Ozluk AA; El-Rayes BF; Akce M
Curr Oncol; 2023 Nov; 30(11):9789-9812. PubMed ID: 37999131
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies.
Ouyang T; Kan X; Zheng C
Front Oncol; 2022; 12():898964. PubMed ID: 35785169
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease.
Cassese G; Han HS; Lee B; Lee HW; Cho JY; Panaro F; Troisi RI
World J Hepatol; 2022 Oct; 14(10):1862-1874. PubMed ID: 36340753
[TBL] [Abstract][Full Text] [Related]
15. Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center.
Ng KYY; Wong LWJ; Ang AJS; Tan SH; Choo SP; Tai DW; Lee JJX
Asia Pac J Clin Oncol; 2021 Oct; 17(5):e249-e261. PubMed ID: 32875742
[TBL] [Abstract][Full Text] [Related]
16. Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.
Yin X; Wu T; Lan Y; Yang W
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35075482
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives.
Federico P; Petrillo A; Giordano P; Bosso D; Fabbrocini A; Ottaviano M; Rosanova M; Silvestri A; Tufo A; Cozzolino A; Daniele B
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33080958
[TBL] [Abstract][Full Text] [Related]
18. Real-World Use of Immunotherapy for Hepatocellular Carcinoma.
Sara A; Ruff SM; Noonan AM; Pawlik TM
Pragmat Obs Res; 2023; 14():63-74. PubMed ID: 37637511
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma.
Shen W; Chen Y; Lei P; Sheldon M; Sun Y; Yao F; Ma L
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291797
[TBL] [Abstract][Full Text] [Related]
20. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.
Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST
Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]